138 related articles for article (PubMed ID: 10382940)
1. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus.
Tsuchiya Y; Onda M; Miyashita M; Sasajima K
Med Oncol; 1999 Apr; 16(1):31-7. PubMed ID: 10382940
[TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
Yamamoto K; Oka M; Hayashi H; Tangoku A; Gondo T; Suzuki T
Cancer; 1997 May; 79(9):1647-55. PubMed ID: 9128978
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
4. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels.
Kashiwabara K; Nakamura H; Esaki T
Clin Chim Acta; 2000 Apr; 294(1-2):105-13. PubMed ID: 10727677
[TBL] [Abstract][Full Text] [Related]
5. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus.
Nakamura T; Ide H; Eguchi R; Hayashi K; Takasaki K; Watanabe S
Dis Esophagus; 1998 Jan; 11(1):35-9. PubMed ID: 9595230
[TBL] [Abstract][Full Text] [Related]
6. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
7. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma.
Kato H; Takita J; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Anticancer Res; 2003; 23(4):3263-72. PubMed ID: 12926062
[TBL] [Abstract][Full Text] [Related]
8. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus.
Nakamura T; Ide H; Eguchi R; Hayashi K; Takasaki K; Watanabe S
Dis Esophagus; 2017 Nov; 11(1):35-39. PubMed ID: 29040480
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
Quillien V; Raoul JL; Laurent JF; Meunier B; Le Prise E
Oncol Rep; 1998; 5(6):1561-5. PubMed ID: 9769406
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1.
Pradier O; Hille A; Schmiberger H; Hess CF
Cancer Radiother; 2002 Feb; 6(1):15-21. PubMed ID: 11899676
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck.
Ogawa T; Tsurusako Y; Kimura N; Nishioka S; Akagi H; Nishizaki K; Nishioka K; Rutka J
Acta Otolaryngol Suppl; 1999; 540():72-6. PubMed ID: 10445084
[TBL] [Abstract][Full Text] [Related]
14. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
15. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
18. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of serum high-mobility group box 1 detection in esophageal squamous cell carcinoma].
Chen CG; Cui L; Tang P; Yu ZT
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):838-41. PubMed ID: 24061989
[TBL] [Abstract][Full Text] [Related]
20. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Dong J; Zeng BH; Xu LH; Wang JY; Li MZ; Zeng MS; Liu WL
J Transl Med; 2010 Sep; 8():81. PubMed ID: 20813067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
